Author:
Disis Mary L.,Knutson Keith L.,Schiffman Kathy,Rinn Kristine,McNeel Douglas G.
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA: Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16–20, 1994
2. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181(6): 2109–2117, 1995
3. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same Her-2/neuderived peptide. Proc Natl Acad Sci USA 92: 432–436, 1995
4. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer. J Clin Oncol 15(11): 3363–3367, 1997
5. Frazer IH, Collins EJ, Fox JS, Jones B, Oliphant RC, Mackay IR: Assessment of delayed-type hypersensitivity in man: a comparison of the ‘Multitest’ and conventional intradermal injectin of six antigens. Clin Immunol Immunopathol 35(2): 182–190, 1985
Cited by
131 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献